CytImmune To Present At ASCO Phase I Clinical Trial of CYT-6091 to be Presented on June 3, 2007
ROCKVILLE, Md., April 4, 2007 -- CytImmune, a clinical stage nanomedicine company focused on the development and commercialization of multifunctional, tumor-targeted therapies has been selected to present a poster abstract at the 43rd American Society of Clinical Oncology Annual Meeting in Chicago Illinois, June 1-5. The poster session will take place from 8:00 am to 12 noon on June 3. Dr. Lawrence Tamarkin, CEO of CytImmune will present the poster abstract entitled "Preliminary Results of a Phase I clinical trial of CYT-6091: A pegylated colloidal gold TNF nanomedicine.
"Acceptance to ASCO provides CytImmune the opportunity to present
its research to the leading body of international oncology
experts," said Dr. Lawrence Tamarkin, CEO of CytImmune Sciences.
"For an emerging company, it's a chance interact with those in the
field, advance science and demonstrate our role in the fight
against cancer."
CYT-6091 (Aurimune), CytImmune's lead drug compound, is recombinant
human tumor necrosis factor alpha (TNF) bound to the surface of 27
nanometer pegylated colloidal gold nanoparticles. While TNF's tumor
killing properties are well documented, its clinical use has been
severely limited due to unacceptable toxicities. To harness the
potential of this anti-cancer agent, CytImmune's approach
simultaneously binds PEG-Thiol and TNF to the surface of colloidal
gold nanoparticles, whose design is to: (1) make them invisible to
immune detection, thereby avoiding uptake by the liver and spleen
and (2) target delivery of TNF directly to tumor sites. At 27
nanometers in size, CYT-6091 is able to exit the blood stream
through leaky blood vessels and sequester in and around tumor sites
with TNF binding to available receptors in this area. Preclinical
studies indicate that CYT-6091 is then able to actively and
passively target tumors, potentially delivering more drug to the
site of disease with reduced side effects. The mechanism of
targeting solid tumors is independent of tumor type. Phase I
clinical trials for CYT-6091 (Aurimune) began in May 2006 at the
NCI Center for Cancer Research, Bethesda, MD.
Phase I preliminary trial data will be released according to ASCO's
Abstract Policy, in which the information is confidential from the
time of submission until the time the information is made publicly
available at the ASCO Annual Meeting. The American Society of
Clinical Oncology Annual Meeting is considered the premier
educational and scientific event in the oncology community. In
2006, more than 29,000 attendees from around the world participated
in the 42nd ASCO annual meeting in Atlanta, Georgia.
ABOUT CYTIMMUNE
CytImmune Sciences is a clinical stage nanomedicine company focused on the development and commercialization of multifunctional, tumor-targeted therapies harnessing the unique properties of gold nanoparticles, known anti-cancer agents and biology of tumors. The platform technology allows for the targeted delivery of anti-caner therapies while avoiding update by healthy organs and tissues leading to improved efficacy, safety and patient outcomes. CytImmune hopes to build from this common core technology a family of therapeutics with faster development timelines, efficient regulatory approvals, new commercialization value, and greater patient benefits.
Contact:
Alicia Moran
703-739-2424x110
Posted: April 2007
